Progressive familial intrahepatic cholestasis (PFIC) also known as Byler's disease, is an autosomal recessive disease leading to hepatic fibrosis, cirrhosis, and progressive hepatic failure (
1) and is considered among the five leading causes of liver transplantation (
2). Its estimated prevalence is 1:50000-100000 in general population (
3). The disease occurs in early childhood and is diagnosed by clinical manifestations, ultrasound examination, liver biopsy, and specific tests to rule out other childhood cholestatic disorders (
3). The pathologic features are nonspecific. Nonetheless, typical laboratory measures such as low to normal levels of gamma globulin transpeptidase (GGT), absence of lipoprotein X, low cholesterol, and high bile acids are usually observed (
2). The pathophysiology seems to reside in hepatocellular damage resulting from concentrated biliary compounds (2). Severe pruritus is a disabling symptom in PFIC. Therefore, facilitating biliary salts extraction brings a major contribution to treatment (
4). There is no treatment of choice for PFIC. Symptomatic treatment consists of ursodeoxycholic acid (UDCA), effective in only 60% of patients (
5). Before 1990, the treatment of choice in unresponsive patients was liver transplantation (
1). However, transplantation is largely limited by the availability of the organ and significant mortality and morbidity (
6). Such obstacles have led to the introduction of diversion approaches to shortcut biliary compounds out of the liver. Nevertheless, the choice of surgical intervention is not agreed. Therefore, we decided to evaluate a new internal diversion approach in a patient diagnosed with PFIC.